Неклассические эффекты силденафила в клинической медицине: междисциплинарный подход

Based on the results of modern clinical and experimental studies, the review article discusses issues of pharmacotherapeutic feasibility, pathogenetic validity and safety of the first and most studied phosphodiesterase type 5 inhibitor – sildenafil – in general clinical practice according to «non-classical» (non-erectogenic) indications in the framework of an interdisciplinary approach modern medicine. As it is known, at present, phosphodiesterase type 5 inhibitors are both the «first line» therapy for treating erectile dysfunction (as monotherapy), as well as an effective option for monotherapy or combined pharmacotherapy of lower urinary tract symptoms on the background of benign prostatic hyperplasia in men with erectile dysfunction. However, given the universality and fundamentality of the mechanisms of their pharmacological action (first of all, the effect on the metabolism of one of the key vasomodulators of the vascular bed, nitric oxide NO), the list of potential and promising indications for prescribing these drugs is constantly expanding due to the presence of various «non-classical» (non-erectogenic) effects, which makes them very attractive for wider application not only in urological practice, but also in other medical specialties. The article describes in more detail and purposefully the accumulated to date scientific and practical data on the effectiveness of the use and potential mechanisms of action of sildenafil in cardiology, endocrinology, neurology, nephrology, obstetrics and gynecology, andrological reproductology and oncology, and also presents the results of studies confirming its safety in the treatment of relevant specialized diseases.

• Publication year

  2019

• Venue

  Unknown venue

• Publication date

  2019-01-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.21518/2079-701X-2018-21-192-202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of 'Diabesity': Beyond Pharmacotherapy.

  2018cited by this paper
• RETRACTED ARTICLE: Utero-placental perfusion Doppler indices in growth restricted fetuses: effect of sildenafil citrate

  2018cited by this paper
• Sildenafil During Pregnancy: A Preclinical Meta-Analysis on Fetal Growth and Maternal Blood Pressure

  2017cited by this paper
• Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction.

  2017cited by this paper
• High prevalence of erectile dysfunction in diabetes: a systematic review and meta‐analysis of 145 studies

  2017cited by this paper
• The Effect of Oral Phosphodiesterase-5 Inhibitors on Sperm Parameters: A Meta-analysis and Systematic Review.

  2017cited by this paper
• Phosphodiesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7

  2017cited by this paper
• Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial.

  2017cited by this paper
• Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double-blind randomised control trial

  2016cited by this paper
• Systematic review and meta‐analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction

  2016cited by this paper
• Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension.

  2016cited by this paper
• Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis

  2016cited by this paper
• The role of cGMP and its signaling pathways in kidney disease.

  2016cited by this paper
• MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions.

  2016cited by this paper
• Maternal Administration of Sildenafil Citrate Alters Fetal and Placental Growth and Fetal–Placental Vascular Resistance in the Growth-Restricted Ovine Fetus

  2016cited by this paper
• Transplacental sildenafil rescues lung abnormalities in the rabbit model of diaphragmatic hernia

  2016cited by this paper
• Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial

  2016cited by this paper
• Sildenafil in Pregnancy: A Systematic Review of Maternal Tolerance and Obstetric and Perinatal Outcomes

  2016cited by this paper
• Phosphodiesterase type 5 inhibitors and kidney disease

  2015cited by this paper
• Prevention of valproic acid-induced neural tube defects by sildenafil citrate.

  2015cited by this paper
• Targeted Protection of Donor Graft Vasculature Using a Phosphodiesterase Inhibitor Increases Survival and Predictability of Autologous Fat Grafts

  2015cited by this paper
• Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial.

  2015cited by this paper
• PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

  2015cited by this paper
• PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types

  2015cited by this paper
• Potential Therapeutic Role of Phosphodiesterase Type 5 Inhibition in Hypertension and Chronic Kidney Disease

  2014cited by this paper
• Phosphodiesterase 5 Inhibitors Enhance Chemotherapy Killing in Gastrointestinal/Genitourinary Cancer Cells

  2014cited by this paper
• PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells

  2014cited by this paper
• How to Treat Erectile Dysfunction in Men with Diabetes: from Pathophysiology to Treatment

  2014cited by this paper
• Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond.

  2014cited by this paper
• The protective effects of a phosphodiesterase 5 inhibitor, sildenafil, on postresuscitation cardiac dysfunction of cardiac arrest: metabolic evidence from microdialysis

  2014cited by this paper
• Protective effects of sildenafil citrate administration on cisplatin-induced ovarian damage in rats

  2014cited by this paper
• Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO/SIRT1/PGC-1α signaling.

  2014cited by this paper
• Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials

  2014cited by this paper
• Sildenafil and cardioprotection.

  2013cited by this paper
• Sildenafil attenuates placental ischemia-induced hypertension.

  2013cited by this paper
• Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation.

  2013cited by this paper
• Seminal vesicles and diabetic neuropathy: ultrasound evaluation after prolonged treatment with a selective phosphodiesterase‐5 inhibitor

  2013cited by this paper
• Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

  2013cited by this paper
• Increased cGMP promotes healthy expansion and browning of white adipose tissue

  2013cited by this paper
• Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin Signaling

  2013cited by this paper
• Preconditioning by Phosphodiesterase‐5 Inhibition Improves Therapeutic Efficacy of Adipose‐Derived Stem Cells Following Myocardial Infarction in Mice

  2012cited by this paper
• Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors.

  2012cited by this paper
• Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity

  2012cited by this paper
• Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy: A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging With Myocardial Tagging

  2012cited by this paper
• Type 2 diabetes mellitus and testosterone: a meta-analysis study.

  2011cited by this paper
• Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway.

  2011cited by this paper
• PDE-5 and NOS II mRNA expression in menopausal women: a molecular biology study

  2011cited by this paper
• Phosphodiesterases and cardiac cGMP: evolving roles and controversies.

  2011cited by this paper
• Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors

  2011cited by this paper
• Inhibition of PDE5 by Sulindac Sulfide Selectively Induces Apoptosis and Attenuates Oncogenic Wnt/β-Catenin–Mediated Transcription in Human Breast Tumor Cells

  2011cited by this paper
• Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice.

  2011cited by this paper
• Is sildenafil citrate affect endometrial receptivity? an immunohistochemical study

  2011cited by this paper
• Reduced Vascular Nitric Oxide–cGMP Signaling Contributes to Adipose Tissue Inflammation During High-Fat Feeding

  2011cited by this paper
• Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction

  2010cited by this paper
• Endometrial growth and uterine blood flow: a pilot study for improving endometrial thickness in the patients with a thin endometrium.

  2010cited by this paper
• Early combined treatment with sildenafil and adipose-derived mesenchymal stem cells preserves heart function in rat dilated cardiomyopathy

  2010cited by this paper
• Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes

  2010cited by this paper
• Treatment options for sexual dysfunction in patients with chronic kidney disease: a systematic review of randomized controlled trials.

  2010cited by this paper
• Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion

  2009cited by this paper
• Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review.

  2009cited by this paper
• Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients

  2009cited by this paper
• Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice

  2009cited by this paper
• cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse Myocardium

  2009cited by this paper
• Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes

  2008cited by this paper
• Oral phosphodiesterase-5 inhibitors and sperm functions

  2008cited by this paper
• Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection.

  2008cited by this paper
• Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity.

  2008cited by this paper
• Metabolic syndrome, testosterone deficiency and erectile dysfunction never come alone

  2008cited by this paper
• Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial.

  2008cited by this paper
• Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3β*

  2008cited by this paper
• Impact of a long-term sildenafil treatment on pressor response in conscious rats with insulin resistance and hypertriglyceridemia.

  2008cited by this paper
• Erectile dysfunction: a marker of early coronary heart disease.

  2007cited by this paper
• Adenosine A(1) receptor mediates delayed cardioprotective effect of sildenafil in mouse.

  2007cited by this paper
• Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility

  2007cited by this paper
• Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits.

  2007cited by this paper
• Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice.

  2007cited by this paper
• Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes.

  2007cited by this paper
• ED2: erectile dysfunction = endothelial dysfunction.

  2007cited by this paper
• Chronic Treatment With Sildenafil Improves Energy Balance and Insulin Action in High Fat–Fed Conscious Mice

  2007cited by this paper
• A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour

  2007cited by this paper
• PDE5 inhibitors in diabetic peripheral neuropathy

  2006cited by this paper
• Successful Use of Vaginal Sildenafil Citrate in Two Infertility Patients with Asherman's Syndrome

  2006cited by this paper
• Physiological role of ROCKs in the cardiovascular system.

  2006cited by this paper
• Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure

  2006cited by this paper
• Changes in incidence of diabetes in U.S. adults, 1997-2003.

  2006cited by this paper
• Suppression of cyclic GMP‐specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells

  2005cited by this paper
• Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

  2005cited by this paper
• Treatment of sexual dysfunctions secondary to male infertility with sildenafil citrate.

  2004cited by this paper
• Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure

  2004cited by this paper
• Modulatory Effect of the PDE-5 Inhibitor Sildenafil in Diabetic Neuropathy

  2004cited by this paper
• Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function.

  2004cited by this paper
• Exisulind and CP248 induce growth inhibition and apoptosis in human esophageal adenocarcinoma and squamous carcinoma cells.

  2003cited by this paper
• Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.

  2003cited by this paper
• Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.

  2003cited by this paper
• Diabesity: An Inflammatory Metabolic Condition

  2003cited by this paper
• Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation.

  2003cited by this paper
• Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.

  2003cited by this paper
• Use of cGMP PDE5 inhibitors in the treatment of neuropathy: a review of the patent literature.

  2002cited by this paper
• Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review.

  2002cited by this paper
• Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes.

  2002cited by this paper

• No citing papers are available for this paper.